Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine.
In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.
On the venture capital front, there has been a great deal of market activity. In January 2016, Exosome Diagnostics closed $60 million in Series B financing, which it followed in July 2017 with $30 million in Series C financing. Similarly, Codiak Biosciences was launched in 2016 when the MD Anderson Cancer Center joined two venture capital firms to form the company with more than $80 million in series A and B financing. On November 29, 2017, Codiak BioSciences added another $76.5 million in Series C financing. In total across its Series A, B, and C financing rounds, Codiak Biosciences raised an astonishing $168.5 million.
In May 2017, ExCoBio Inc. raised US $11 million in a Series A funding round. ExoCoBio is a venture-backed startup that develops exosome-based cosmeceuticals and biopharmaceuticals for skin and tissue regeneration that is headquartered in South Korea.
Australian biotech company VivaZome Therapeutics was awarded a grant of $2.18M in December 2017 to support the project: Enabling Exosome Therapy: Developing an Advanced Manufacturing Process. It received the funds under the Australian government’s Advanced Manufacturing Scheme.
While exosomes derived from multiple stem cell types are being explored, mesenchymal stem cell (MSC) derived exosomes are best represented within the scientific literature and global patent activity.
They are also attracting the largest investment. In one recent example, Dr. Krishnamurthy and Dr. Zhang of the the UAB Department of Biomedical Engineering received a $2.64 million grant from the U.S. NIH to “study whether mesenchymal stem cells or their exosomes can boost dead cell removal and also reduce damaging inflammation after heart attacks in animal models of diabetes.”
To characterize this rapidly forming marketplace, BioInformant has released a 134-page market report that explores growing demand for exosome therapeutics, diagnostics, research tools, consumer care products, and manufacturing technologies.
It also reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials, and present social analytics from Google Trends and Google Adwords.
Claim it to:
- Identify the five market segments that compose the industry
- Reveal the market players competing in each niche
- Identify opportunities for exosome product development
- Access market size determinations and projections through 2022
Companies Mentioned Include:
- Anjarium Biosciences
- Avalon GloboCare Corp.
- Beckman Coulter
- Capricor Therapeutics
- Cavadis B.V.
- Cell Guidance Systems
- Codiak Biosciences
- CosmoBio USA
- Creative Medical Technologies Holdings
- Exiqon
- ExoCoBio Inc.
- Exerkine Corporation
- Exopharm
- Exosome Diagnostics
- Evox Therapeutics
- Exogenus Therapeutics
- Exosome Sciences
- Exosomics Siena SpA
- Exostemtech Co. Ltd.
- Exovita Biosciences
- Galen Lab Supplies
- Guangzhou Selaira Stem Cell Technology Co., Ltd
- HansaBioMed Life Sciences
- iZon Science
- Kimera Labs
- Lonza
- Miltenyi Biotec
- Norgen Biotek
- ReNeuron
- RoosterBio
- Unicyte AG
- VivaZome Therapeutics
- ZenBio
Learn more here: Market for Stem Cell Exosomes
As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.